- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01373320
Faith Moves Mountains: A Community Based Participatory Research (CBPR) Appalachian Wellness & Cancer Prevention Program
October 21, 2013 updated by: Nancy Schoenberg
Faith Moves Mountains: A CBPR Appalachian Wellness & Cancer Prevention Program
The study purpose is to evaluate the effectiveness of a set of culturally appropriate, faith-placed lay health advisor interventions aimed at facilitating smoking cessation and increasing cancer screening among Appalachian participants.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
The developmental phase of this project incorporated community based participatory research (CBPR) principles to identify the needs and preferences of community members with regard to cancer prevention.
In the intervention phase, this group-randomized trial administers and evaluates a set of culturally appropriate interventions aimed at facilitating smoking cessation and increasing cancer screening among participants in 6 distressed Appalachian counties.
Faith institutions are recruited and randomized to treatment or wait-list control conditions, and participants are recruited and enrolled within those institutions.
Participants select one or more targeted health behaviors from a menu including smoking cessation, colorectal cancer screening, cervical cancer screening, and breast cancer screening, and subsequently receive the intervention(s) aimed at their selected health behaviors.
Study Type
Interventional
Enrollment (Actual)
1415
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Kentucky
-
Whitesburg, Kentucky, United States
- Faith Moves Mountains
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- For smoking cessation: age 18 or older; current cigarette smoker; able to provide informed consent
- For cervical cancer screening: female; age 18 or older AND outside of screening guidelines; able to provide informed consent
- For breast cancer screening: female; age 40 or older AND outside of screening guidelines; able to provide informed consent
- For colorectal cancer screening: age 40 or older AND outside of screening guidelines; able to provide informed consent
Exclusion Criteria:
- For smoking cessation: None
- For cervical cancer screening: History of cervical cancer; history of hysterectomy
- For breast cancer screening: History of breast cancer
- For colorectal cancer screening: History of colorectal cancer
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Early Intervention
Participants in this group are nested in churches which were randomly assigned to the treatment group.
|
For smoking cessation: Cooper-Clayton group sessions plus motivational interviewing, both delivered by local lay health advisor. For all cancer screenings: lay health advisor home visits incorporating motivational interviewing and focused on decreasing participant-identified barriers to screening. |
|
No Intervention: Delayed Intervention
Participants in this group are nested in churches which were randomly assigned to the wait-list control group.
They receive an educational luncheon focused on stress reduction during the intervention window for the Early Intervention group, and subsequently receive the intervention(s) for their selected target health behaviors at a later date.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Proportion of participants reporting the health behavior of interest (depending on which intervention component(s) were selected)
Time Frame: Assessed approximately 4 months after baseline
|
For smoking cessation: Self-reported smoking status.
For cancer screenings: Self-reported receipt of cervical, breast, and/or colorectal cancer screening.
This assessment occurs after the Early Treatment group has completed the intervention.
|
Assessed approximately 4 months after baseline
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in stage of readiness to change the selected health behavior(s) from baseline
Time Frame: Assessed approximately 4 months after baseline
|
Measured using reliable and valid instruments which were pretested in focus groups comprised of members of the target population.
Positive change (i.e., increasing stage of readiness) from baseline to post-test will be coded as "1," while negative or no change will be coded "0."
This assessment occurs after the Early Treatment group has completed the intervention.
|
Assessed approximately 4 months after baseline
|
|
Number of visits completed
Time Frame: Approximately 4 months after baseline
|
This process measure will reflect the number of visits/classes attended by participants, as a means of assessing participation rate and feasibility.
|
Approximately 4 months after baseline
|
|
Retention (i.e., number of participants who complete all planned assessment timepoints)
Time Frame: Approximately one year after baseline
|
Retention numbers will be assessed as a process measure outcome.
Participants who complete all study assessment timepoints will be coded as "1," while participants who drop out will be coded "0." Number/percentage of participants who remained enrolled and complete all study procedures and assessments will be used as an indicator of feasibility in the community setting.
|
Approximately one year after baseline
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Nancy Schoenberg, Ph.D., University Of Kentucky
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
March 1, 2010
Primary Completion (Actual)
November 1, 2012
Study Completion (Actual)
November 1, 2012
Study Registration Dates
First Submitted
June 10, 2011
First Submitted That Met QC Criteria
June 13, 2011
First Posted (Estimate)
June 14, 2011
Study Record Updates
Last Update Posted (Estimate)
October 23, 2013
Last Update Submitted That Met QC Criteria
October 21, 2013
Last Verified
October 1, 2013
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Digestive System Diseases
- Neoplasms
- Urogenital Neoplasms
- Neoplasms by Site
- Uterine Neoplasms
- Genital Neoplasms, Female
- Uterine Cervical Diseases
- Uterine Diseases
- Gastrointestinal Neoplasms
- Digestive System Neoplasms
- Gastrointestinal Diseases
- Colonic Diseases
- Intestinal Diseases
- Intestinal Neoplasms
- Rectal Diseases
- Uterine Cervical Neoplasms
- Colorectal Neoplasms
Other Study ID Numbers
- R24MD002757 (U.S. NIH Grant/Contract)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Cervical Cancer
-
University of California, San DiegoWithdrawnCervical Cancer | Cervical Cancer Stage | Cervical Cancer Stage IB2 | Cervical Cancer Stage IB1 | Cervical Cancer Stage I | Cervical Cancer Stage IB | Cervical Cancer Stage II | Cervical Cancer Stage IIa | Cervical Cancer, Stage IIB | Cervical Cancer, Stage III | Cervical Cancer Stage IIIB | Cervical Cancer... and other conditionsUnited States
-
M.D. Anderson Cancer CenterWithdrawnStage IB3 Cervical Cancer FIGO 2018 | Stage II Cervical Cancer FIGO 2018 | Stage IIA Cervical Cancer FIGO 2018 | Stage IIA1 Cervical Cancer FIGO 2018 | Stage IIA2 Cervical Cancer FIGO 2018 | Stage IIB Cervical Cancer FIGO 2018 | Stage III Cervical Cancer FIGO 2018 | Stage IIIA Cervical Cancer FIGO... and other conditions
-
Tata Memorial HospitalMahidol University; Juntendo University; Gunma University; Chiang Mai University...RecruitingStage IIA Cervical Cancer FIGO 2018 | Stage IIB Cervical Cancer FIGO 2018 | Stage IIIA Cervical Cancer FIGO 2018 | Stage IIIB Cervical Cancer FIGO 2018 | Stage IVA Cervical Cancer FIGO 2018 | Stage IB Cervical Cancer FIGO 2018India, Japan, Thailand
-
Mayo ClinicNational Cancer Institute (NCI)Active, not recruitingCervical Adenosquamous Carcinoma | Cervical Squamous Cell Carcinoma, Not Otherwise Specified | Recurrent Cervical Carcinoma | Stage IB3 Cervical Cancer FIGO 2018 | Stage II Cervical Cancer FIGO 2018 | Stage IIA Cervical Cancer FIGO 2018 | Stage IIA1 Cervical Cancer FIGO 2018 | Stage IIA2 Cervical... and other conditionsUnited States
-
Abramson Cancer Center of the University of PennsylvaniaWithdrawnCervical Cancer | Stage IB Cervical Cancer | Stage IIA Cervical Cancer | Stage IIB Cervical Cancer | Stage III Cervical Cancer | Stage IVA Cervical Cancer
-
Qi ZhouNot yet recruitingCervical Cancer Recurrent | Cervical Cancer Metastatic
-
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityNot yet recruitingCervical Cancer Recurrent | Cervical Cancer Metastatic
-
National Cancer Institute (NCI)CompletedCervical Adenocarcinoma | Cervical Squamous Cell Carcinoma | Stage IB Cervical Cancer | Stage IIA Cervical Cancer | Stage IIB Cervical Cancer | Stage III Cervical Cancer | Stage IVA Cervical Cancer | Stage IVB Cervical CancerUnited States
-
M.D. Anderson Cancer CenterRecruitingCervical Large Cell Neuroendocrine Carcinoma | Cervical Neuroendocrine Carcinoma | Cervical Small Cell Carcinoma | Cervical Undifferentiated Carcinoma | Stage I Cervical Cancer AJCC v8 | Stage IA Cervical Cancer AJCC v8 | Stage IA1 Cervical Cancer AJCC v8 | Stage IA2 Cervical Cancer AJCC v8 | Stage... and other conditionsUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruitingStage IA Cervical Cancer | Stage IB Cervical Cancer | Stage IA1 Cervical Cancer | Stage IA2 Cervical Cancer | Stage IB1 Cervical Cancer | Stage IB2 Cervical Cancer | Stage IB3 Cervical CancerUnited States
Clinical Trials on Lay health advisor interactions
-
MetroHealth Medical CenterTerminated
-
National Institute of Environmental Health Sciences...Terminated
-
Nancy SchoenbergNational Cancer Institute (NCI)CompletedCervical CancerUnited States
-
Ohio State University Comprehensive Cancer CenterNational Cancer Institute (NCI)Completed
-
Centers for Disease Control and PreventionCompletedHIV Infections | Gonorrhea | Chlamydia Infections | SyphilisUnited States
-
University of Maryland, College ParkCompletedInformation Dissemination | Evidence-Based Public HealthUnited States
-
Stanford UniversityNational Institute on Minority Health and Health Disparities (NIMHD); National...CompletedCancer | End of LifeUnited States
-
University of Southern CaliforniaCenters for Disease Control and Prevention; Association of American Medical...Completed
-
University of California, San FranciscoNational Institute on Minority Health and Health Disparities (NIMHD)Recruiting
-
Palo Alto Veterans Institute for ResearchUnited States Department of Defense; US Department of Veterans AffairsRecruitingLung Adenocarcinoma | Lung Carcinoma | Lung Cancer, Non-Small Cell | Lung Cancer, Small Cell | Lung Cancer (NSCLC) | Lung Adenocarcinoma With Bronchiolo-alveolar FeatureUnited States